<DOC>
	<DOC>NCT01838291</DOC>
	<brief_summary>Observational, open label, prospective, multi-center, post-marketing drug surveillance program.</brief_summary>
	<brief_title>Active Drug Surveillance Program of Ferriprox Use</brief_title>
	<detailed_description>A post-marketing, drug surveillance program evaluating the use, monitoring, benefits and adverse effects of Ferriprox under clinical conditions in newly treated patients.</detailed_description>
	<mesh_term>Iron Overload</mesh_term>
	<mesh_term>Deferiprone</mesh_term>
	<criteria>Main Patients who started Ferriprox therapy less than one month or are to initiate Ferriprox therapy at the time of enrolment into the program. Main Patients treated with Ferriprox for more than one month prior to enrolment.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Ferriprox</keyword>
	<keyword>Deferiprone</keyword>
	<keyword>DFP</keyword>
	<keyword>L1</keyword>
</DOC>